Pizotifen inhibits the proliferation and invasion of gastric cancer cells

Jiang,Ying; Wang,Wei; Wu,Xi; Shi,Jihua

doi:10.3892/etm.2019.8308

Pizotifen inhibits the proliferation and invasion of gastric cancer cells

Authors:
- Ying Jiang
- Wei Wang
- Xi Wu
- Jihua Shi
View Affiliations

Affiliations: Department of Gastroenterology, National Center of Gerontology, Beijing Hospital, Beijing 100730, P.R. China
Published online on: December 9, 2019 https://doi.org/10.3892/etm.2019.8308
Pages: 817-824
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is the fifth most common malignancy and the third highest cause of cancer‑associated mortality worldwide. Therefore, research on the pathogenesis of gastric cancer is of utmost importance. It has been reported that aberrant activation of the Wnt/β‑catenin signaling pathway is involved in the occurrence and development of gastric cancer. In the present study, it was found that pizotifen could inhibit the viability of gastric cancer cell lines MNK45 and AGS cells in a dose‑dependent manner. Pizotifen treatment suppressed cell migration and invasion in MNK45 and AGS cells, whilst also inducing apoptosis. Western blot analysis demonstrated that pizotifen blocked the expression of Wnt3a, β‑catenin and N‑cadherin, whilst increasing E‑cadherin expression. In addition, BML‑284, a pharmacological Wnt signaling activator, partially reversed the changes in the expression levels of β‑catenin, N‑cadherin and E‑cadherin in MNK45 and AGS cells induced by pizotifen. Collectively, these findings suggested that pizotifen demonstrates potential as a novel anti‑cancer drug for the treatment of gastric cancer by inhibiting the Wnt/β‑catenin pathway.

View Figures

View References

1	Carlomagno N, Santangelo ML, Amato B, Calogero A, Saracco M, Cremone C, Miranda A, Dodaro C and Renda A: Total colectomy for cancer: Analysis of factors linked to patients' age. Int J Surg. 12 (Suppl 2):S135–S139. 2014. View Article : Google Scholar : PubMed/NCBI
2	Strand MS, Lockhart AC and Fields R: Genetics of gastric cancer. Surg Clin North Am. 97:345–370. 2017. View Article : Google Scholar : PubMed/NCBI
3	Hamashima C: Current issues and future perspectives of gastric cancer screening. World J Gastroenterol. 20:13767–13774. 2014. View Article : Google Scholar : PubMed/NCBI
4	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
5	Baker NE: Transcription of the segment-polarity gene wingless in the imaginal discs of drosophila, and the phenotype of a pupal-lethal wg mutation. Development. 102:489–497. 1988.PubMed/NCBI
6	Croce JC and McClay DR: Evolution of the Wnt pathways. Methods Mol Biol. 469:3–18. 2008. View Article : Google Scholar : PubMed/NCBI
7	Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
8	Rapp J, Jaromi L, Kvell K, Miskei G and Pongracz JE: WNT signaling - lung cancer is no exception. Respir Res. 18:1672017. View Article : Google Scholar : PubMed/NCBI
9	Byun T, Karimi M, Marsh JL, Milovanovic T, Lin F and Holcombe RF: Expression of secreted Wnt antagonists in gastrointestinal tissues: Potential role in stem cell homeostasis. J Clin Pathol. 58:515–519. 2005. View Article : Google Scholar : PubMed/NCBI
10	Barker N, Huch M, Kujala P, van de Wetering M, Snippert HJ, van Es JH, Sato T, Stange DE, Begthel H, van den Born M, et al: Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell. 6:25–36. 2010. View Article : Google Scholar : PubMed/NCBI
11	Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, Siu HC, Deng S, Chu KM, Law S, et al: Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 46:573–582. 2014. View Article : Google Scholar : PubMed/NCBI
12	Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
13	Nagaoka T, Karasawa H, Turbyville T, Rangel MC, Castro NP, Gonzales M, Baker A, Seno M, Lockett S, Greer YE, et al: Cripto-1 enhances the canonical Wnt/β-catenin signaling pathway by binding to LRP5 and LRP6 co-receptors. Cell Signal. 25:178–189. 2013. View Article : Google Scholar : PubMed/NCBI
14	Garinis GA, Spanakis NE, Menounos PG, Manolis EN and Peros G: Transcriptional impairment of beta-catenin/E-cadherin complex is not associated with beta-catenin mutations in colorectal carcinomas. Br J Cancer. 88:206–209. 2003. View Article : Google Scholar : PubMed/NCBI
15	Kikuchi A, Yamamoto H, Sato A and Matsumoto S: New insights into the mechanism of Wnt signaling pathway activation. Int Rev Cell Mol Biol. 291:21–71. 2011. View Article : Google Scholar : PubMed/NCBI
16	Micalizzi DS, Farabaugh SM and Ford HL: Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 15:117–134. 2010. View Article : Google Scholar : PubMed/NCBI
17	Peng Z, Wang CX, Fang EH, Wang GB and Tong Q: Role of epithelial-mesenchymal transition in gastric cancer initiation and progression. World J Gastroenterol. 20:5403–5410. 2014. View Article : Google Scholar : PubMed/NCBI
18	Yue H, Tang B, Zhao Y, Niu Y, Yin P, Yang W, Zhang Z and Yu P: MIR-519d suppresses the gastric cancer epithelial-mesenchymal transition via Twist1 and inhibits Wnt/β-catenin signaling pathway. Am J Transl Res. 9:3654–3664. 2017.PubMed/NCBI
19	Cho ES, Kang HE, Kim NH and Yook JI: Therapeutic implications of cancer epithelial-mesenchymal transition (EMT). Arch Pharm Res. 42:14–24. 2019. View Article : Google Scholar : PubMed/NCBI
20	Fuchs R, Schwach G, Stracke A, Meier-Allard N, Absenger M, Ingolic E, Haas HS, Pfragner R and Sadjak A: The anti-hypertensive drug prazosin induces apoptosis in the medullary thyroid carcinoma cell line TT. Anticancer Res. 35:31–38. 2015.PubMed/NCBI
21	Lin OA, Karim ZA, Vemana HP, Espinosa EV and Khasawneh FT: The antidepressant 5-HT_2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. PLoS One. 9:e870262014. View Article : Google Scholar : PubMed/NCBI
22	Speight TM and Avery GS: Pizotifen(BC-105): A review of its pharmacological properties and its therapeutic efficacy in vascular headaches. Drugs. 3:159–203. 1972. View Article : Google Scholar : PubMed/NCBI
23	Ahmadi AA, Shadifar M, Ataee R, Vaillancourt C, Ataee A, Oufkir T and Jafari-Sabet M: The serotonin 5-HT_2A receptor antagonist ritanserin induces apoptosis in human colorectal cancer and acts in synergy with curcumin. Int Biol Biomed J. 1:56–65. 2015.
24	Liu J, Wu X, Mitchell B, Kintner C, Ding S and Schultz PG: A small-molecule agonist of the Wnt signaling pathway. Angew Chem Int Ed Engl. 44:1987–1990. 2005. View Article : Google Scholar : PubMed/NCBI
25	Cheng YY, Yu J, Wong YP, Man EP, To KF, Jin VX, Li J, Tao Q, Sung JJ, Chan FK and Leung WK: Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer. 97:895–901. 2007. View Article : Google Scholar : PubMed/NCBI
26	Hanaki H, Yamamoto H, Sakane H, Matsumoto S, Ohdan H, Sato A and Kikuchi A: An anti-Wnt5a antibody suppresses metastasis of gastric cancer cells in vivo by inhibiting receptor-mediated endocytosis. Mol Cancer Ther. 11:298–307. 2012. View Article : Google Scholar : PubMed/NCBI
27	Ataee R, Ajdary S, Zarrindast M, Rezayat M and Hayatbakhsh MR: Anti-mitogenic and apoptotic effects of 5-HT1B receptor antagonist on HT29 colorectal cancer cell line. J Cancer Res Clin Oncol. 136:1461–1469. 2010. View Article : Google Scholar : PubMed/NCBI
28	Soll C, Riener MO, Oberkofler CE, Hellerbrand C, Wild PJ, DeOliveira ML and Clavien PA: Expression of serotonin receptors in human hepatocellular cancer. Clin Cancer Res. 18:5902–5910. 2012. View Article : Google Scholar : PubMed/NCBI
29	Vicentini LM, Cattaneo MG and Fesce R: Evidence for receptor subtype cross-talk in the mitogenic action of serotonin on human small-cell lung carcinoma cells. Eur J Pharmacol. 318:497–504. 1996. View Article : Google Scholar : PubMed/NCBI
30	Soll C, Jang JH, Riener MO, Moritz W, Wild PJ, Graf R and Clavien PA: Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology. 51:1244–1254. 2010. View Article : Google Scholar : PubMed/NCBI
31	Dizeyi N, Hedlund P, Bjartell A, Tinzl M, Austild-Taskén K and Abrahamsson PA: Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. Urol Oncol. 29:436–445. 2011. View Article : Google Scholar : PubMed/NCBI
32	Siddiqui EJ, Shabbir MA, Mikhailidis DP, Mumtaz FH and Thompson CS: The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. BJU Int. 97:634–639. 2006. View Article : Google Scholar : PubMed/NCBI
33	Hirokawa Y, Yip KH, Tan CW and Burgess AW: Colonic myofibroblast cell line stimulates colonoid formation. Am J Physiol Gastrointest Liver Physiol. 306:G547–G556. 2014. View Article : Google Scholar : PubMed/NCBI
34	Byun MR, Hwang JH, Kim AR, Kim KM, Hwang ES, Yaffe MB and Hong JH: Canonical Wnt signalling activates TAZ through PP1A during osteogenic differentiation. Cell Death Differ. 21:854–863. 2014. View Article : Google Scholar : PubMed/NCBI
35	Bu G, Lu W, Liu CC, Selander K, Yoneda T, Hall C, Keller ET and Li Y: Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases. Int J Cancer. 123:1034–1042. 2008. View Article : Google Scholar : PubMed/NCBI
36	He S, Lu Y, Liu X, Huang X, Keller ET, Qian CN and Zhang J: Wnt3a: Functions and implications in cancer. Chin J Cancer. 34:554–562. 2015. View Article : Google Scholar : PubMed/NCBI
37	Pan KF, Liu WG, Zhang L, You WC and Lu YY: Mutations in components of the Wnt signaling pathway in gastric cancer. World J Gastroenterol. 14:1570–1574. 2008. View Article : Google Scholar : PubMed/NCBI
38	Kahn M: Can we safely target the WNT pathway? Nat Rev Drug Discov. 13:513–532. 2014. View Article : Google Scholar : PubMed/NCBI
39	Mook RA Jr, Wang J, Ren XR, Chen M, Spasojevic I, Barak LS, Lyerly HK and Chen W: Structure-activity studies of Wnt/β-catenin inhibition in the niclosamide chemotype: Identification of derivatives with improved drug exposure. Bioorg Med Chem. 23:5829–5838. 2015. View Article : Google Scholar : PubMed/NCBI
40	Steinhart Z, Pavlovic Z, Chandrashekhar M, Hart T, Wang X, Zhang X, Robitaille M, Brown KR, Jaksani S, Overmeer R, et al: Corrigendum: Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. Nat Med. 23:13842017. View Article : Google Scholar : PubMed/NCBI
41	Kim H, Yoo SB, Sun P, Jin Y, Jheon S, Lee CT and Chung JH: Alteration of the E-cadherin/β-catenin complex is an independent poor prognostic factor in lung adenocarcinoma. Korean J Pathol. 47:44–51. 2013. View Article : Google Scholar : PubMed/NCBI
42	Cheng XX, Wang ZC, Chen XY, Sun Y, Kong QY, Liu J, Gao X, Guan HW and Li H: Frequent loss of membranous E-cadherin in gastric cancers: A cross-talk with Wnt in determining the fate of beta-catenin. Clin Exp Metastasis. 22:85–93. 2005. View Article : Google Scholar : PubMed/NCBI